LY2874455 + phosphate binders

This is a combination therapy consisting of **LY2874455**, an oral, selective, pan-fibroblast growth factor receptor (FGFR) inhibitor, and **phosphate binders**. LY2874455 is a small-molecule inhibitor developed by Eli Lilly, primarily investigated for use in various solid-organ cancers, notably gastric cancer and non-small cell lung cancer. Its mechanism of action is inhibition of FGFR1-4, leading to antitumor effects through suppression of FGFR signaling. A prominent pharmacodynamic effect of LY2874455 is the induction of hyperphosphatemia due to FGFR blockade, often necessitating the co-administration of phosphate binders to control serum phosphorus levels during therapy. Phosphate binders are a heterogeneous group of agents used to reduce serum phosphate, primarily in patients with chronic kidney disease or drug-induced hyperphosphatemia; they work by binding dietary phosphate in the gastrointestinal tract, reducing its absorption. Common phosphate binder agents include sevelamer, calcium acetate, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide[1][2][5].